All articles by Miranda Mclaren

The rare disease revolution: The state of play for CGTs in orphan diseases

Rare diseases are chronic conditions that affect between 3.5% and 5.9% of the global population. About 80% of rare diseases…
Commercialising drugs in Europe: Lean models for first-time launchers

In 2025, 193 innovative drugs received approval in Europe, including 133 new molecular entities (NMEs). Over half – 56% -…
Lyophilisation is growing in pharma, but technical challenges persist

Lyophilisation, or freeze drying, is the process in which a liquid drug is converted into a stable powder via sublimation,…
China-ready by design: Leveraging NMPA’s new 30‑working day IND pathway

Over the last decade, China has become a key destination for oncology clinical trials, with Chinese sites increasingly incorporated within…
Why manual aseptic filling often provides faster start dates than automated lines

A Phase 1 start date may be tied to investor milestones. A rare disease therapy may represent a small patient…

Biomarkers in Nephrology Research: From Exploratory to Decision-Making Tools

While strategic use of biomarkers in clinical trials has traditionally been associated with oncology, the potential for growth across other…
Annex 1 sterilisation: Why pharma packaging strategy is changing

The revised EU GMP Annex 1 has ushered in a new phase for sterile manufacturing. Published in 2022, with most…
Early Biomarkers as Predictors of Nephrology Trial Trajectory

Chronic kidney disease (CKD) and other nephrology conditions are a major global health challenge. With rising prevalence and persistent unmet…
The evolution of the ADC market – and what it means for commercial packaging

The ADC market The first antibody drug conjugate (ADC) was approved in 2000 by pairing a cytotoxic chemotherapy agent with…
Complementing DepMap: Expanding the toolkit for oncology target discovery and de-risking

With cancer responsible for one in six deaths around the world, precision medicines based on the root cause of the…

Sections